Keros Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Keros Therapeutics, Inc. (KROS) reported Increase (Decrease) in Accrued Liabilities of -$3.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-03
- Keros Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $2.22M, a 17.02% decline year-over-year.
- Keros Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$5.22M.
- Keros Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$4.43M.
- Keros Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$4.79M, a 155.08% decline year-over-year.
- Keros Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$10.13M, a 443.19% decline from fiscal 2024.
- Keros Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $2.95M, a 43.85% decline from fiscal 2023.
- Keros Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $5.26M, a 1.22% decline from fiscal 2022.
- Keros Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $5.32M, a 100.68% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$3.00M 10-Q · filed 2026-08-03 | -$7.43M derived: sum of 3 quarters · filed 2026-08-03 | -$12.22M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$5.22M 10-Q · filed 2026-05-14 | -$9.65M derived: sum of 2 quarters · filed 2026-05-14 | -$14.44M derived: sum of 3 quarters · filed 2026-05-14 | -$11.77M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$9.22M derived: sum of 2 quarters · filed 2026-03-04 | -$6.55M derived: sum of 3 quarters · filed 2026-08-03 | -$10.13M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$4.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$2.12M derived: sum of 2 quarters · filed 2026-08-03 | -$5.70M 10-Q · filed 2025-11-05 | -$7.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$906.00K 10-Q · filed 2026-08-03 | -$2.21M derived: sum of 3 quarters · filed 2026-08-03 | $6.50M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$3.58M 10-Q · filed 2026-05-14 | -$4.88M derived: sum of 2 quarters · filed 2026-05-14 | $3.83M derived: sum of 3 quarters · filed 2026-05-14 | $4.73M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $7.41M derived: sum of 2 quarters · filed 2026-03-04 | $8.31M derived: sum of 3 quarters · filed 2026-03-04 | $2.95M 10-K · filed 2026-03-04 |
| 2024-09-30 | $8.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $9.61M derived: sum of 2 quarters · filed 2025-11-05 | $4.25M 10-Q · filed 2025-11-05 | $10.04M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $900.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$4.45M 10-Q · filed 2025-08-06 | $1.33M derived: sum of 3 quarters · filed 2025-08-06 | $1.61M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$5.35M 10-Q · filed 2025-05-06 | $433.00K derived: sum of 2 quarters · filed 2025-05-06 | $707.00K derived: sum of 3 quarters · filed 2025-05-06 | $1.88M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $5.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $6.06M derived: sum of 2 quarters · filed 2025-02-26 | $7.23M derived: sum of 3 quarters · filed 2025-02-26 | $5.26M 10-K · filed 2025-02-26 |
| 2023-09-30 | $274.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.45M derived: sum of 2 quarters · filed 2024-11-06 | -$530.00K 10-Q · filed 2024-11-06 | $3.73M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$804.00K 10-Q · filed 2024-08-07 | $3.46M derived: sum of 3 quarters · filed 2025-02-26 | $4.74M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$1.98M 10-Q · filed 2024-05-08 | $2.29M derived: sum of 2 quarters · filed 2025-02-26 | $3.57M derived: sum of 3 quarters · filed 2025-02-26 | $2.98M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $4.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $5.54M derived: sum of 2 quarters · filed 2025-02-26 | $4.96M derived: sum of 3 quarters · filed 2025-02-26 | $5.32M 10-K · filed 2025-02-26 |
| 2022-09-30 | $1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $698.00K derived: sum of 2 quarters · filed 2023-11-06 | $1.06M 10-Q · filed 2023-11-06 | $962.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$583.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$222.00K 10-Q · filed 2023-08-07 | -$319.00K derived: sum of 3 quarters · filed 2024-02-28 | $1.33M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $361.00K 10-Q · filed 2023-05-04 | $264.00K derived: sum of 2 quarters · filed 2024-02-28 | $1.92M derived: sum of 3 quarters · filed 2024-02-28 | $2.12M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.55M derived: sum of 2 quarters · filed 2024-02-28 | $1.76M derived: sum of 3 quarters · filed 2024-02-28 | $2.65M 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.85M derived: sum of 2 quarters · filed 2022-11-03 | $2.75M 10-Q · filed 2022-11-03 | $2.66M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $204.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.10M 10-Q · filed 2022-08-04 | $1.01M derived: sum of 3 quarters · filed 2022-08-04 | $2.67M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $894.00K 10-Q · filed 2022-05-05 | $809.00K derived: sum of 2 quarters · filed 2022-05-05 | $2.46M derived: sum of 3 quarters · filed 2022-05-05 | $213.00K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $1.57M derived: sum of 2 quarters · filed 2022-03-09 | -$681.00K derived: sum of 3 quarters · filed 2022-03-09 | $2.59M 10-K · filed 2022-03-09 |
| 2020-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$596.00K derived: sum of 2 quarters · filed 2021-11-04 | $2.67M 10-Q · filed 2021-11-04 | $2.70M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.02M 10-Q · filed 2021-08-05 | $1.05M derived: sum of 3 quarters · filed 2021-08-05 | $1.96M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $3.27M 10-Q · filed 2021-05-06 | $3.30M derived: sum of 2 quarters · filed 2021-05-06 | $4.21M derived: sum of 3 quarters · filed 2021-05-06 | $4.29M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $936.00K derived: sum of 2 quarters · filed 2021-03-25 | $1.01M derived: sum of 3 quarters · filed 2021-03-25 | $1.19M 10-K · filed 2021-03-25 |
| 2019-09-30 | $910.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $988.00K derived: sum of 2 quarters · filed 2020-11-10 | $1.17M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $255.00K 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $177.00K 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |